The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksShield Thera Share News (STX)

Share Price Information for Shield Thera (STX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.55
Bid: 1.50
Ask: 1.60
Change: 0.00 (0.00%)
Spread: 0.10 (6.667%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1.55
STX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Wressle boosts Europa Oil, Egdon and Union Jack

Thu, 16th Dec 2021 10:56

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

----------

AIM - WINNERS

----------

Shield Therapeutics PLC, up 27% at 37.00 pence, 12-month range 27.01p-66.00p. The Newcastle, England-based pharmaceutical company says patient access for its Accrufer iron deficiency product rises. Shield secures payer coverage with "several large pharmacy benefit managers" in US. This boosts Accrufer access to roughly 40 million patients.

----------

Europa Oil & Gas Holdings PLC, up 15% at 1.24 pence, 12-month range 1.00p-2.20p. Rises on production update from Wressle hydrocarbon development in North Lincolnshire. Wressle has produced at an average of 666 barrels of oil per day over last seven day period. In early 2022, testing will be completed to see "full potential of the well". Europa holds a 30% stake in Wressle. Egdon Resources PLC also owns 30% and Union Jack Oil PLC 40%. Egdon shares are up 11% and Union Jack up 8.4%.

----------

Ceres Power, up 8.1% at 1,005.00 pence, 12-month range 820.50p-1,626.00p. Credit Suisse starts coverage of the stock with an Outperform rating and 1,450p price target.

----------

AIM - LOSERS

----------

boohoo Group PLC, down 16% at 115.56 p, 12-month range 110.00p-378.90p. Retailer lowers sales and margins guidance due to Omicron uncertainty and as product return rates hit net sales. For the financial year ending February 28, boohoo now expects net sales growth in the 12% to 14% range, cut from previous guidance of a rise of 20% to 25%. In three months to November 30, net sale rise 10% annually to GBP506.2 million from GBP460.7 million. On a two-year basis, net sales are 53% higher. Shares fall to a roughly five-year low.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
29 Jan 2021 18:26

TRADING UPDATES: Character Extends Peppa Pig Deal; Dekel Raises Cash

TRADING UPDATES: Character Extends Peppa Pig Deal; Dekel Raises Cash

Read more
21 Jan 2021 20:12

DIRECTOR DEALINGS SUMMARY: New U&I Group CEO Upton Buys Shares

DIRECTOR DEALINGS SUMMARY: New U&I Group CEO Upton Buys Shares

Read more
19 Jan 2021 15:04

DIRECTOR DEALINGS: Shield Therapeutics CEO Buys 100,000 Shares

DIRECTOR DEALINGS: Shield Therapeutics CEO Buys 100,000 Shares

Read more
15 Jan 2021 13:11

IN BRIEF: Shield Therapeutics Expects Increase In Annual Revenue

IN BRIEF: Shield Therapeutics Expects Increase In Annual Revenue

Read more
14 Dec 2020 16:59

UK DIRECTOR DEALINGS SUMMARY: Tracsis CFO Sells GBP480,000 In Shares

UK DIRECTOR DEALINGS SUMMARY: Tracsis CFO Sells GBP480,000 In Shares

Read more
11 Dec 2020 16:40

IN BRIEF: Shield Therapeutics Shares Drop As Eyes US Push On Its Own

IN BRIEF: Shield Therapeutics Shares Drop As Eyes US Push On Its Own

Read more
19 Oct 2020 17:34

IN BRIEF: Shield Therapeutics Notes Teva Withdrawing Patent Opposition

IN BRIEF: Shield Therapeutics Notes Teva Withdrawing Patent Opposition

Read more
19 Oct 2020 09:12

Shield shares rise as Teva withdraws patent oppositions

(Sharecast News) - Commercial-stage pharmaceutical company Shield Therapeutics updated the market on its opposition proceedings with Teva Pharmaceutical Industries on Monday, confirming that Teva had withdrawn its appeal and opposition over two of Shield's patents.

Read more
16 Sep 2020 11:13

Shield Therapeutics Swings To Profit As It Makes Feraccru Progress

Shield Therapeutics Swings To Profit As It Makes Feraccru Progress

Read more
7 Aug 2020 06:56

IN BRIEF: Shield Therapeutics' Product Offers Alternative For Anaemia

IN BRIEF: Shield Therapeutics' Product Offers Alternative For Anaemia

Read more
16 Jul 2020 21:19

IN BRIEF: Shield Therapeutics Notes PT20 Paper Publication

IN BRIEF: Shield Therapeutics Notes PT20 Paper Publication

Read more
26 Jun 2020 17:19

UK EXECUTIVE CHANGE SUMMARY: John Menzies Chief Executive Steps Down

UK EXECUTIVE CHANGE SUMMARY: John Menzies Chief Executive Steps Down

Read more
11 Jun 2020 16:17

UK Shareholder Meetings Calendar - Next 7 Days

UK Shareholder Meetings Calendar - Next 7 Days

Read more
3 Jun 2020 15:57

Shield Therapeutics shares rise on two recent research papers

(Sharecast News) - Commercial stage pharmaceutical company Shield Therapeutics reported the recent publication of two papers concerning its 'Feraccru' or 'Accrufer' product on Wednesday.

Read more
26 May 2020 14:22

UK EXECUTIVE CHANGE SUMMARY: New Chairs For Matomy And Shield

UK EXECUTIVE CHANGE SUMMARY: New Chairs For Matomy And Shield

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.